Cargando…

Quantitative monitoring of minimal residual disease in childhood acute lymphoblastic leukemia using TEL‐AML1 fusion transcript as a marker

IMPORTANCE: By demonstrating with TEL‐AML1, this study indicated that mRNAs transcribed from fusion genes are ideal targets for minimal residual disease (MRD) monitoring in childhood acute lymphoblastic leukemia, and that different thresholds are needed to apply them into the risk stratification. OB...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Xiaoxi, Gao, Chao, Cui, Lei, Li, Weijing, Liu, Shuguang, Zhang, Ruidong, Liu, Yi, Wu, Minyuan, Li, Zhigang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331441/ https://www.ncbi.nlm.nih.gov/pubmed/32851270 http://dx.doi.org/10.1002/ped4.12098

Ejemplares similares

DNMT3A mutations in Chinese childhood acute myeloid leukemia
por: Li, Weijing, et al.
Publicado: (2017)

Persistence of TEL-AML1 fusion gene as minimal residual disease has no additive prognostic value in CD 10 positive B-acute lymphoblastic leukemia: a FISH study
por: Mosad, Eman, et al.
Publicado: (2008)

Space-Time Clustering of Childhood Leukemia: Evidence of an Association with ETV6-RUNX1 (TEL-AML1) Fusion
por: Kreis, Christian, et al.
Publicado: (2017)

Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia
por: Mei, Yanyan, et al.
Publicado: (2014)

Correction to: DNMT3A low-expression is correlated to poor prognosis in childhood B-ALL and confers resistance to daunorubicin on leukemic cells
por: Li, Weijing, et al.
Publicado: (2023)

The Leukemia-Associated Fusion Protein MN1-TEL Blocks TEL-Specific Recognition Sequences
por: ter Haar, W. Martijn, et al.
Publicado: (2012)

Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia
por: Rocha, Juliana Maria Camargos, et al.
Publicado: (2016)

Sources of error in measurement of minimal residual disease in childhood acute lymphoblastic leukemia
por: Latham, Sue, et al.
Publicado: (2017)

Optical Genome Mapping for Comprehensive Assessment of Chromosomal Aberrations and Discovery of New Fusion Genes in Pediatric B-Acute Lymphoblastic Leukemia
por: Gao, Huixia, et al.
Publicado: (2022)

Minimal residual disease monitoring via AML1-ETO breakpoint tracing in childhood acute myeloid leukemia
por: Chen, Xiaoyan, et al.
Publicado: (2021)

Circulating microRNAs as minimal residual disease biomarkers in childhood acute lymphoblastic leukemia
por: Rzepiel, Andrea, et al.
Publicado: (2019)

Initially disadvantaged, TEL-AML1 cells expand and initiate leukemia in response to irradiation and cooperating mutations
por: Li, M, et al.
Publicado: (2013)

Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia
por: Kruse, Aaron, et al.
Publicado: (2020)

Minimal residual disease in childhood B Lymphoblastic Leukemia and its correlation with other risk factors
por: Meraj, Fatima, et al.
Publicado: (2020)

Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia
por: Galimberti, Stefania, et al.
Publicado: (2018)

TFDP3 confers chemoresistance in minimal residual disease within childhood T-cell acute lymphoblastic leukemia
por: Chu, Ming, et al.
Publicado: (2016)

Clinical Significance of Minimal Residual Disease at the End of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia
por: Jovanovska, Aleksandra, et al.
Publicado: (2019)

Five distinct biological processes and 14 differentially expressed genes characterize TEL/AML1-positive leukemia
por: Gandemer, Virginie, et al.
Publicado: (2007)

DNMT3A low-expression is correlated to poor prognosis in childhood B-ALL and confers resistance to daunorubicin on leukemic cells
por: Li, Weijing, et al.
Publicado: (2023)

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances
por: Della Starza, Irene, et al.
Publicado: (2019)

Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia: Egyptian Experience
por: Ibrahim, Rasha Ibrahim, et al.
Publicado: (2022)

Minimal Residual Disease-Based Risk Stratification in Chinese Childhood Acute Lymphoblastic Leukemia by Flow Cytometry and Plasma DNA Quantitative Polymerase Chain Reaction
por: Cheng, Suk Hang, et al.
Publicado: (2013)

Inherited GATA3 variant associated with positive minimal residual disease in childhood B‐cell acute lymphoblastic leukemia via asparaginase resistance
por: Li, Chunjie, et al.
Publicado: (2021)

Measurable residual disease in childhood B-cell acute lymphoblastic leukemia
por: Gale, Robert Peter
Publicado: (2022)

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Current Practice and Future Directions
por: Contreras Yametti, Gloria Paz, et al.
Publicado: (2021)

Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia
por: Della Starza, Irene, et al.
Publicado: (2023)

The utility of multiparametric flow cytometry for the detection of minimal residual disease in acute lymphoblastic leukemia
por: Cunha, Fernanda Gonçalves Pereira, et al.
Publicado: (2012)

Minimal residual disease in acute lymphoblastic leukemia: technical aspects and implications for clinical interpretation
por: Kim, In-Suk
Publicado: (2020)

An advanced fragment analysis-based individualized subtype classification of pediatric acute lymphoblastic leukemia
por: Zhang, Han, et al.
Publicado: (2015)

Screening of Novel Pharmacogenetic Candidates for Mercaptopurine-Induced Toxicity in Patients With Acute Lymphoblastic Leukemia
por: Cao, Minyuan, et al.
Publicado: (2020)

Metabolomic profiling identifies pathways associated with minimal residual disease in childhood acute lymphoblastic leukaemia
por: Schraw, Jeremy M., et al.
Publicado: (2019)

Quantification of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) using amplicon-fusion-site polymerase chain reaction (AFS-PCR)
por: Weber, Axel, et al.
Publicado: (2012)

Transcriptome Analysis of Minimal Residual Disease in Subtypes of Pediatric B Cell Acute Lymphoblastic Leukemia
por: Sitthi-amorn, Jitsuda, et al.
Publicado: (2015)

Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia
por: Ikoma, Maura Rosane Valério, et al.
Publicado: (2015)

Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia
por: O’Connor, David, et al.
Publicado: (2018)

Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey
por: Pigneux, Arnaud, et al.
Publicado: (2018)

Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53
por: Gefen, Nir, et al.
Publicado: (2009)

Tel quel
por: Valéry, Paul, 1871-1945
Publicado: (1941)

Minimal Residual Disease Detection and Evolved IGH Clones Analysis in Acute B Lymphoblastic Leukemia Using IGH Deep Sequencing
por: Wu, Jinghua, et al.
Publicado: (2016)

Minimal residual disease detection in Tunisian B-acute lymphoblastic leukemia based on immunoglobulin gene rearrangements
por: Besbes, S., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_uvs4d816flltaufdgq9f1ba8ko